D.C. Diagnosis

D.C. Diagnosis Nicholas Florko

Covid budget crunch looms over government funding fight

D.C. Diagnosis Nicholas Florko

The FDA’s promised menthol ban is about to face a critical test

D.C. Diagnosis Nicholas Florko

Is the Senate gearing up to actually pass drug pricing legislation?

D.C. Diagnosis Nicholas Florko

The new lightning rod in the fight over high drug prices

D.C. Diagnosis Nicholas Florko

A no good, very bad week for Biden’s science agenda

D.C. Diagnosis Nicholas Florko

Democrats aren’t ready to support Biden’s FDA pick, Robert Califf

D.C. Diagnosis Nicholas Florko

What does the Build Back Better Act actually mean for the health care industry?

D.C. Diagnosis Nicholas Florko

Which drug maker spent the most on lobbying this summer? The answer will surprise you

D.C. Diagnosis Nicholas Florko

Scott Gottlieb: Trump’s shadow FDA commissioner during Covid-19?

D.C. Diagnosis Nicholas Florko

Congress is ready to dig into drug prices

D.C. Diagnosis Nicholas Florko

What happened to the FDA’s toughest regulator?

D.C. Diagnosis Nicholas Florko

Biden wants a drug pricing plan in 45 days. Who’s going to write it? 

D.C. Diagnosis Nicholas Florko

Are pharma mergers bad for biotech?

D.C. Diagnosis Nicholas Florko

Operation Warp Speed — now, the ‘CAG’— is here to stay

D.C. Diagnosis Rachel Cohrs

The lonely quest to create a commission to investigate Covid-19

Politics Rachel Cohrs

STAT Plus: There’s no point person in Biden’s HHS for its $187 billion Covid-19 fund for health care providers

D.C. Diagnosis Nicholas Florko

Will this be the most-watched FDA meeting ever?

D.C. Diagnosis STAT Staff

STAT Plus: STAT+ Conversations: The D.C. Diagnosis

STAT+ Conversations Rick Berke, Erin Mershon and Lev Facher

STAT Plus: STAT+ Conversations: How pharma is influencing the 2020 election

D.C. Diagnosis Nicholas Florko

How the drug industry keeps winning in Washington

D.C. Diagnosis Nicholas Florko

So much for Trump’s rule about drug prices in TV ads

D.C. Diagnosis Nicholas Florko

STAT Plus: Digging into the FDA’s grievance hotline

D.C. Diagnosis Nicholas Florko and Lev Facher

It’s a big week for debates about drug prices, whether pharma likes it or not

D.C. Diagnosis Nicholas Florko

STAT Plus: There’s a fight brewing in Congress over pharma’s patents

D.C. Diagnosis Nicholas Florko

How pharma could benefit from one of Congress’ signature drug pricing ideas

D.C. Diagnosis Nicholas Florko

Could we nationalize insulin to make it a ‘public good’?

D.C. Diagnosis Nicholas Florko

Scott Gottlieb is skeptical of the science behind CBD supplements

D.C. Diagnosis Nicholas Florko

STAT Plus: Is pharma’s R&D spending a mark of shame or a point of pride?

D.C. Diagnosis Nicholas Florko

Will the Speaker’s office finally spill the beans on its drug pricing plan?